We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAcer Gdr Reg S Regulatory News (ACID)

Share Price Information for Acer Gdr Reg S (ACID)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: -6.00 (-100.00%)
Open: 7.00
High: 0.00
Low: 0.00
Prev. Close: 7.00
ACID Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

To announce the Company's information

11 Apr 2023 07:00

RNS Number : 7146V
Acer Incorporated
10 April 2023
 

Subject: On behalf of CCI to publicly disclose the merge with ASCBVI (Supplementary Announcement of Nov. 11th, 2022)

Date of events:2023/04/10

Contents:

1.Type of merger and acquisition (e.g., merger, spin-off, acquisition, or share transfer): Merger

2.Date of occurrence of the event: 2023/04/10

3.Names of companies participating in the merger and acquisition (e.g., name of the other company participating in the merger or consolidation, newly established company in a spin-off, acquired company, or company whose shares are taken assignment of):

Acer SoftCapital Incorporated (A Taiwan company, Original company name: Cross Century Investment Limited, "CCI")

Acer SoftCapital Incorporated (A BVI company, "ASCBVI")

4.Counterparty (e.g., name of the other company participating in the merger or consolidation, company taking assignment of the spin-off, or counterparty to the acquisition or assignment of shares):

The surviving company: CCI

The dissolved company: ASCBVI

5.Whether the counterparty of the current transaction is a related party: Yes

6.Relationship between the counterparty and the Company (investee company in which the Company has re-invested and has shareholding of XX%), and explanation of the reasons for the decision to acquire, or take assignment of the shares of, an affiliated enterprise or related person, and whether it will affect shareholders' equity:

CCI and ASCBVI are both subsidiaries of Acer Inc. This merger is to optimize group organization and investment structure. After this merger, CCI is still 100% owned by Acer Inc., so there's no impact on Acer's shareholders' equity.

7.Purpose and conditions of the merger and acquisition, including the reason, consideration conditions and payment schedule of the merger and acquisition:

To optimize group organization and investment structure.

8.Anticipated benefits of the merger and acquisition:

Saving management resource

9.Effect of the merger and acquisition on net worth per share and earnings per share:

There's no impact on net worth per share and earnings per share of Acer Inc.

10.Type of merger consideration and source of funds:

CCI will issue new common shares to ASCBVI's sole shareholder, Acer Inc.

11.Share exchange ratio and basis of its calculation:

The exchange ratio is that each share of ASCBVI to 0.00532278 common shares of CCI.

The basis of the calculation: net worth of ASCBVI and CCI.

12.Whether the CPA, lawyer or securities underwriter issued an unreasonable

opinion regarding the transaction: No

13.Name of the CPA, law or securities firm: HUEI-TAI CAP FIRM

14.Name of the CPA or lawyer: LIN,JIA-HUEI

15.Practice certificate number of the CPA: Taiwan Province CPA No. 4742.

16.Independent expert's report on the reasonableness of the share exchange ratio and the cash or other assets paid to the shareholders (1.The method, principles, or calculations adopted for determination of the public tender offer price, and comparison with the market-value method, cost method, and discounted cash flow method commonly used internationally; 2.comparison of the financial condition, profit status, and price-to-earnings ratio of the subject company with those of TWSE or GTSM listed companies in the same industry; 3.if a price appraisal report of an appraisal organization is taken into account in the public tender offer price, the opinion shall specify the content and conclusion of the appraisal report; and 4.if assets or shares of the subject company, or of the surviving company in the case of a merger, are listed as collateral in the tender offeror's financing repayment plan, the opinion shall disclose the collateralization terms, and assessment of the impact on the financial and operational soundness, of the subject company or of the surviving company of the merger.):

In accordance with the rule of the Accounting Research and Development Foundation (96) No. 113, the calculation is based on the net book value.

17.Scheduled timetable for consummation:

Merger base date is April 10th, 2023. The related matters are planned to be done before Jun. 26th, 2023.

18.Matters related to assumption by the existing company or new company of rights and obligations of the extinguished (or spun-off) company:

CCI will generally assume all rights and obligations of ASCBVI.

19.Basic information of companies participating in the merger:

Company Name: ASCBVI

Main Business: Investment

20.Matters related to the spin-off (including estimated value of the business and assets planned to be assigned to the existing company or new company; the total number and the types and volumes of the shares to be acquired by the split company or its shareholders; matters related to the reduction, if any, in capital of the split company) (note: not applicable other than where there is announcement of a spin-off): Not applicable

21.Conditions and restrictions on future transfers of shares resulting from the merger and acquisition: None

22.Post-merger and acquisition plan:

(1) Willingness to continue operating the business of the company, and the contents of plans to that effect.

(2) Dissolution; delisting from an exchange (or OTC market); material changes in organization, capital, business plan, financial operations and production; accommodation or utilization of staff and assets critical to the Company; or any other matter of material significance that would affect the company's shareholder equity:

CCI will do the original operation activities of ASCBVI and CCI continually.

23.Other important stipulations: None

24.Other important matters concerning the merger and acquisition: None

25.Whether the directors have any objection to the present transaction: No

26.Information regarding directors with personal interest (name of natural person director or name of legal person director and its representative, material interest of the director or the legal person represented by the director (including but not limited to form of actual or expected investment in another company in the merger, shareholding, transaction price, participation in the subject company's business or otherwise, and other terms of investment), reason for recusal or otherwise, details of recusal, and reason for a resolution for or against the merger proposal): None

27.Whether the transaction involved in change of business model: No

28.Details on change of business model: Not applicable

29.Details on transactions with the counterparty for the past year and the expected coming year: None

30.Source of funds: Not applicable

31.Any other matters that need to be specified:

Supplementary Announcement of Nov. 11th, 2022 on 'The Company's board passed a resolution to adjust and optimize the investment structure by share exchange or other appropriate methods.'

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFIFLASIIILIV
Date   Source Headline
18th Apr 202410:15 amRNSTo announce the Company's information
11th Apr 202410:23 amRNSTo announce the Company's information
10th Apr 202410:16 amRNSUn-Audited Monthly Sales Ended Mar. 31, 2024
2nd Apr 20247:00 amRNSTo Announce the Company's Infomation
14th Mar 202410:01 amRNSTo announce the Company's information
7th Mar 20249:45 amRNSUn-Audited Monthly Sales Ended Feb. 29, 2024
26th Feb 20249:38 amRNSTo announce the Company's information
19th Feb 20249:11 amRNSTo announce the Company's information
7th Feb 20248:03 amRNSUn-Audited Monthly Sales Ended Jan. 31, 2024
17th Jan 202410:05 amRNSTo announce the Company's information
8th Jan 20249:24 amRNSUn-Audited Monthly Sales Ended Dec. 31, 2023
27th Dec 20237:00 amRNSTo announce the Company's information
11th Dec 20239:44 amRNSUn-Audited Monthly Sales Ended Nov. 30, 2023
9th Nov 20239:21 amRNSUn-Audited Monthly Sales Ended Oct. 31, 2023
2nd Nov 20239:15 amRNSTo announce the Company's information
24th Oct 20232:34 pmRNSTo announce the Company's information
16th Oct 20237:24 amRNSTo announce the Company's information
11th Oct 202310:36 amRNSUn-Audited Monthly Sales Ended Sep. 30, 2023
26th Sep 202310:07 amRNSTo announce the Company's information
8th Sep 202310:20 amRNSTo announce the Company's sales and information
5th Sep 20237:10 amRNSTo announce the Company's information
23rd Aug 202310:17 amRNSTo announce the Company's information
9th Aug 202310:13 amRNSUn-Audited Monthly Sales Ended July 31, 2023
8th Aug 202312:16 pmRNSTo announce the Company's information
3rd Aug 20231:09 pmRNSTo announce the Company's information
10th Jul 20237:00 amRNSUn-Audited Monthly Sales Ended June 30, 2023
29th Jun 202310:54 amRNSTo announce the Company's information
8th Jun 202310:17 amRNSUn-Audited Monthly Sales Ended May 31, 2023
7th Jun 20237:00 amRNSTo announce the Company's information
9th May 202310:35 amRNSTo announce the Company's info and Monthly Revenue
4th May 202311:14 amRNSTo announce the Company's information
24th Apr 202310:32 amRNSTo announce the Company's information
11th Apr 202311:05 amRNSTo announce the Company's info and Monthly Revenue
11th Apr 20237:00 amRNSTo announce the Company's information
31st Mar 202310:13 amRNSTo announce the Company's information
16th Mar 202310:24 amRNSTo announce the Company's information
10th Mar 20239:06 amRNSUn-Audited Monthly Sales Ended Feb. 28, 2023
8th Mar 20232:23 pmRNSTo announce the Company's information
2nd Mar 20239:05 amRNSTo announce the Company's information
10th Feb 20239:05 amRNSUn-Audited Monthly Sales Ended Jan. 31, 2023
9th Jan 202310:07 amRNSUn-Audited Monthly Sales Ended Dec. 31, 2022
4th Jan 20239:56 amRNSTo announce the Company's information
16th Dec 20229:12 amRNSTo announce the Company's information
9th Dec 20229:06 amRNSUn-Audited Monthly Sales Ended Nov. 30, 2022
8th Dec 20229:20 amRNSTo announce the Company's information
5th Dec 20229:13 amRNSTo announce the Company's information
29th Nov 202211:14 amRNSTo announce the Company's information
9th Nov 20229:23 amRNSUn-Audited Monthly Sales Ended Oct. 31, 2022
8th Nov 20228:50 amRNSTo announce the Company's information
3rd Nov 202210:04 amRNSTo announce the Company's information

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.